Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
Exercise tolerance
Heart failure
Soluble urokinase-type plasminogen activator receptor
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
08
08
2019
accepted:
08
11
2019
pubmed:
20
11
2019
medline:
15
12
2020
entrez:
20
11
2019
Statut:
ppublish
Résumé
Soluble urokinase-type plasminogen activator receptor (suPAR) is a membrane-binding protein that is released into the blood stream by immune activation. Recent reports suggest that circulating suPAR levels are associated with adverse cardiovascular outcomes. Exercise tolerance is an independent predictor of prognosis in patients with heart failure (HF); however, the relationship between serum suPAR level and exercise tolerance is unclear. We prospectively enrolled 94 patients who were hospitalized for worsening of HF. All patients underwent a symptom-limited cardiopulmonary exercise test to evaluate exercise tolerance. The median value of serum suPAR was 4848 pg/ml. During follow up, 44 patients (47%) were admitted for all-cause mortality and re-hospitalization for HF. Median serum suPAR was significantly higher in the patients with cardiac events than in the patients with non-event group. Patients were divided into two groups according to circulating suPAR levels. Kaplan-Meier analysis demonstrated that adverse cardiac events were significantly higher in the high suPAR group (log-rank p = 0.023). Multivariate analysis revealed that suPAR was independently correlated with the parameters of exercise tolerance such as anaerobic threshold (p = 0.007) and peak oxygen uptake (p = 0.005). suPAR levels predicted adverse cardiac events and independently correlated with the parameters of exercise tolerance. suPAR could be a useful surrogate biomarker of exercise tolerance in patients with HF.
Identifiants
pubmed: 31741050
doi: 10.1007/s00380-019-01538-3
pii: 10.1007/s00380-019-01538-3
doi:
Substances chimiques
Biomarkers
0
PLAUR protein, human
0
Receptors, Urokinase Plasminogen Activator
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-688Subventions
Organisme : The Nakatomi Foundation
ID : 2018.29.(1)-3
Organisme : The Mitsui Sumitomo Insurance Welfare Foundation
ID : 2017.2.(1).4
Références
Huang M, Mazar AP, Parry G, Higazi AA, Kuo A, Cines DB (2005) Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1–143). Acta Crystallogr D Biol Crystallogr 61:697–700
doi: 10.1107/S0907444905014174
Thuno M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27:157–172
doi: 10.1155/2009/504294
Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932–943
doi: 10.1038/nrm977
Masucci MT, Pedersen N, Blasi F (1991) A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 266:8655–8658
pubmed: 1851152
Pliyev BK (2009) Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem 321:111–122
doi: 10.1007/s11010-008-9925-z
Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F (2009) 1359–1364
doi: 10.1073/pnas.022652999
Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296–308
doi: 10.1111/j.1365-2796.2010.02252.x
Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J (2015) Soluble urokinase receptor and chronic kidney disease. N Engl J Med 373:1916–1925
doi: 10.1056/NEJMoa1506362
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PaFCS C (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23(6):2051–2059. https://doi.org/10.1111/j.0269-8463.2004.00900.x
doi: 10.1681/ASN.2012030302
Dalos D, Spinka G, Schneider M, Wernly B, Paar V, Hoppe U, Litschauer B, Strametz-Juranek J, Sponder M (2019) New cardiovascular biomarkers in ischemic heart disease-GDF-15, a probable predictor for ejection fraction. J Clin Med. https://doi.org/10.3390/jcm8070924
doi: 10.3390/jcm8070924
pubmed: 31426462
pmcid: 6724012
Persson M, Östling G, Smith G, Hamrefors V, Melander O, Hedblad B, Engström G (2008) Plant species traits are the predominant control on litter decomposition rates within biomes worldwide. Ecology Letters 11(10):1065–23
doi: 10.1161/STROKEAHA.113.003305
Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mortl D, Berger R, Goliasch G, Wojta J, Hulsmann M, Niessner A (2017) Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure. JACC Heart Fail 5:268–277
doi: 10.1016/j.jchf.2016.12.008
Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292:344–350
doi: 10.1001/jama.292.3.344
Miura Y, Fukumoto Y, Miura T, Shimada K, Asakura M, Kadokami T, Ando S, Miyata S, Sakata Y, Daida H, Matsuzaki M, Yasuda S, Kitakaze M, Shimokawa H (2013) Impact of physical activity on cardiovascular events in patients with chronic heart failure. A multicenter prospective cohort study. Circ J 77:2963–2972
doi: 10.1253/circj.CJ-13-0746
Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR (1991) Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786
doi: 10.1161/01.CIR.83.3.778
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–1852
doi: 10.1161/CIR.0b013e31829e8807
Gustafsson A, Ventorp F, Wisén AG, Ohlsson L, Ljunggren L, Westrin Å (2017) Effects of acute exercise on circulating soluble form of the urokinase receptor in patients with major depressive disorder. Biomark Insights 12:1177271917704193
doi: 10.1177/1177271917704193
Rohde C, Polcwiartek C, Andersen E, Vang T, Nielsen J (2018) Effect of a physical activity intervention on suPAR levels: a randomized controlled trial. J Sci Med Sport 21:286–290
doi: 10.1016/j.jsams.2017.06.018
Haupt TH, Rasmussen LJH, Kallemose T, Ladelund S, Andersen O, Pisinger C, Eugen-Olsen J (2019) Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun aging 16:1
doi: 10.1186/s12979-018-0141-8
Sponder M, Lichtenauer M, Wernly B, Paar V, Hoppe U, Emich M, Fritzer-Szekeres M, Litschauer B, Strametz-Juranek J (2019) Serum heart-type fatty acid-binding protein decreases and soluble isoform of suppression of tumorigenicity 2 increases significantly by long-term physical activity. J Investig Med 67:833–840
doi: 10.1136/jim-2018-000913
McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446
doi: 10.1056/NEJM197112232852601
Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ (2016) Focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 133:e694–711
doi: 10.1161/CIR.0000000000000406
Baba R, Nagashima M, Goto M, Nagano Y, Yokota M, Tauchi N, Nishibata K (1996) Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol 28:1567–1572
doi: 10.1016/S0735-1097(96)00412-3
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, CdtJefe GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992
doi: 10.1053/j.ajkd.2008.12.034
Westin O, Rasmussen LJH, Andersen O, Buch E, Olsen JE, Friberg J (2018) Soluble urokinase plasminogen activator receptor (suPAR) as a predictor of incident atrial fibrillation. J Atr Fibrillation 10:1801
pubmed: 29988279
pmcid: 6009789
Cardiology WGoCREPaWGoHFotESo (2001) Recommendations for exercise testing in chronic heart failure patients. Eur Heart J 22:37–45
doi: 10.1053/euhj.2000.2388
Shibata A, Hanatani A, Izumi Y, Kitada R, Iwata S, Yoshiyama M (2018) Serum brain-derived neurotrophic factor level and exercise tolerance complement each other in predicting the prognosis of patients with heart failure. Heart Vessels 33:1325–1333
doi: 10.1007/s00380-018-1174-9
Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M (2005) Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 111:996–1005
doi: 10.1161/01.CIR.0000156469.96135.0D
Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J, Investigators HAS (2010) Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 55:2129–2137
doi: 10.1016/j.jacc.2009.12.045
Mikkelsen UR, Couppé C, Karlsen A, Grosset JF, Schjerling P, Mackey AL, Klausen HH, Magnusson SP, Kjær M (2013) Life-long endurance exercise in humans: circulating levels of inflammatory markers and leg muscle size. Mech aging Dev 134:531–540
doi: 10.1016/j.mad.2013.11.004
Palacios G, Pedrero-Chamizo R, Palacios N, Maroto-Sánchez B, Aznar S, González-Gross M, Group ES (2015) Biomarkers of physical activity and exercise. Nutr Hosp 31(Suppl 3):237–244
Sanchis-Gomar F, Bonaguri C, Pareja-Galeano H, Gomez-Cabrera MC, Candel J, Viña J, Lippi G (2013) Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor (suPAR). Clin Lab 59(3):207–210. https://doi.org/10.1111/nph.13832
doi: 10.7754/Clin.Lab.2012.120728
Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11:23–36
doi: 10.1038/nrm2821
Fujisaka T, Fujita SI, Maeda D, Shibata K, Takahashi H, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N (2017) Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction. Heart Vessels 32:1327–1336
doi: 10.1007/s00380-017-1002-7